scholarly journals Guillain-Barré Syndrome Heralding the Diagnosis of Hodgkin Lymphoma: A Case Report

2020 ◽  
Vol 12 (3) ◽  
pp. 365-372
Author(s):  
Alawi Aqel Al-Attas ◽  
Abdulrahman Yousef Aldayel ◽  
Sara Abdullah Al Najjar ◽  
Saleh Mansoor Alkhonezan
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Ivig Therapy ◽  
Hodgkin's Lymphoma ◽  
Guillain Barre Syndrome ◽  
Ivig Treatment ◽  
Dramatic Improvement ◽  
Guillain Barré Syndrome ◽  
Guillain Barré ◽  
Tomography Scan ◽  
Fluid Test

Lymphoma is a prevalent type of lymphoid tissue malignancy that is seldom associated with Guillain-Barré syndrome (GBS). In the majority of instances, both Hodgkin’s and non-Hodgkin’s lymphoma are not proceeded by GBS. Here, we report on a case of a young patient with a manifestation and investigation suggestive of GBS, signaling an unconfirmed diagnosis of Hodgkin’s lymphoma. A cerebrospinal fluid test revealed an albuminocytological dissociation with a noteworthy rise in protein (2.32 g/L). The patient was initiated on intravenous immunoglobulin (IVIG) treatment and then showed dramatic improvement after the third dose of IVIG. His constitutional presentation alongside high inflammatory labs prompted further investigation. An enhanced pan-computed tomography scan showed multiple enlarged mediastinal and hilar lymph nodes that were confirmed as Hodgkin’s lymphoma after biopsy. Brentuximab was initiated immediately after IVIG therapy. This case highlights consideration of Hodgkin’s lymphoma as a differential diagnosis under the auspices of GBS.

scholarly journals Guillain-Barré syndrome in a patient with non-Hodgkin's lymphoma

2000 ◽  
Vol 11 (2) ◽  
pp. 217-220 ◽  
Author(s):  
D. Re ◽  
A. Schwenk ◽  
P. Hegener ◽  
S. Bamborschke ◽  
V. Diehl ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Guillain Barre Syndrome ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

scholarly journals Variant Guillain-Barré Syndrome in a Patient with Non-Hodgkin’s Lymphoma

2015 ◽  
Vol 2015 ◽  
pp. 1-4
Author(s):  
R. H. Bishay ◽  
J. Paton ◽  
V. Abraham
Keyword(s):  
B Cell ◽  
Hodgkin’S Lymphoma ◽  
Axonal Neuropathy ◽  
Hodgkin's Lymphoma ◽  
Guillain Barre Syndrome ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Guillain Barré Syndrome ◽  
Guillain Barré ◽  
Large B Cell

We report a 72-year-old female patient with diffuse large B cell non-Hodgkin’s lymphoma (NHL) with previous treatment with standard chemotherapy presenting as an acute, ascending, sensorimotor polyneuropathy. Nerve conduction studies and lumbar puncture supported a rare, but ominous, axonal variant of Guillain-Barré Syndrome (GBS) known as acute motor and sensory axonal neuropathy (AMSAN), which is distinguished from the more common, acute demyelinating forms of GBS. Previous reports have largely focused on toxicities secondary to chemo- or radiotherapy as a major contributor to the development of acute neuropathies in malignancy. Clinicians should also be mindful of direct neoplastic invasion or, less commonly, paraneoplastic phenomenon, as alternative mechanisms, the latter possibly reflecting immune dysregulation in particularly aggressive lymphomas. At the time of writing, this is the first report in the literature of an axonal variant of GBS in a patient with diffuse large B cell NHL. A discussion regarding common and uncommon neuropathies in haematological malignancies is made, with a brief review of the anecdotal evidence supporting a paraneoplastic association with GBS or its variant forms in the setting of lymphoma.

Albumin levels as a biomarker for second Intravenous Immunoglobulin (IVIG) treatment in Guillain-Barre syndrome (GBS)

2020 ◽  
Vol 74 ◽  
pp. 247-249 ◽  
Author(s):  
Anna Shalman ◽  
Shiri Savir ◽  
Yana Mechnik Steen ◽  
Andrey Ovanyan ◽  
Nancy Boniel ◽  
...  
Keyword(s):  
Intravenous Immunoglobulin ◽  
Guillain Barre Syndrome ◽  
Ivig Treatment ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

scholarly journals IVIG Treatment and Prognosis in Guillain–Barré Syndrome

2010 ◽  
Vol 30 (S1) ◽  
pp. 74-78 ◽  
Author(s):  
Pieter A. van Doorn ◽  
Krista Kuitwaard ◽  
Christa Walgaard ◽  
Rinske van Koningsveld ◽  
Liselotte Ruts ◽  
...  
Keyword(s):  
Guillain Barre Syndrome ◽  
Ivig Treatment ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

scholarly journals Intravenous immunoglobulin treatment for mild Guillain-Barré syndrome: an international observational study

2021 ◽  
pp. jnnp-2020-325815
Author(s):  
Christine Verboon ◽  
Thomas Harbo ◽  
David R Cornblath ◽  
Richard A C Hughes ◽  
Pieter A van Doorn ◽  
...  
Keyword(s):  
Supportive Care ◽  
Intravenous Immunoglobulin ◽  
Guillain Barre Syndrome ◽  
Study Entry ◽  
Ivig Treatment ◽  
Disease Course ◽  
Disability Score ◽  
Residual Symptoms ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

ObjectiveTo compare the disease course in patients with mild Guillain-Barré syndrome (GBS) who were treated with intravenous immunoglobulin (IVIg) or supportive care only.MethodsWe selected patients from the prospective observational International GBS Outcome Study (IGOS) who were able to walk independently at study entry (mild GBS), treated with one IVIg course or supportive care. The primary endpoint was the GBS disability score four weeks after study entry, assessed by multivariable ordinal regression analysis.ResultsOf 188 eligible patients, 148 (79%) were treated with IVIg and 40 (21%) with supportive care. The IVIg group was more disabled at baseline. IVIg treatment was not associated with lower GBS disability scores at 4 weeks (adjusted OR (aOR) 1.62, 95% CI 0.63 to 4.13). Nearly all secondary endpoints showed no benefit from IVIg, although the time to regain full muscle strength was shorter (28 vs 56 days, p=0.03) and reported pain at 26 weeks was lower (n=26/121, 22% vs n=12/30, 40%, p=0.04) in the IVIg treated patients. In the subanalysis with persistent mild GBS in the first 2 weeks, the aOR for a lower GBS disability score at 4 weeks was 2.32 (95% CI 0.76 to 7.13). At 1 year, 40% of all patients had residual symptoms.ConclusionIn patients with mild GBS, one course of IVIg did not improve the overall disease course. The certainty of this conclusion is limited by confounding factors, selection bias and wide confidence limits. Residual symptoms were often present after one year, indicating the need for better treatments in mild GBS.

Sign in / Sign up

Export Citation Format

Share Document